$ASMB
Assembly Biosciences Inc Stock $asmb

$asmb Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000114420418058118 Filed on November 08, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q4
Revenue	$3.735M	$4.286M	$3.315M
YoY Change	12.67%	61.15%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$8.810M	$7.750M	$5.000M
YoY Change	76.2%	85.41%	53.85%
% of Gross Profit
Research & Development	$21.25M	$19.11M	$10.60M
YoY Change	100.47%	74.84%	22.97%
% of Gross Profit
Depreciation & Amortization	$170.0K	$200.0K	$100.0K
YoY Change	70.0%	377.94%	400.0%
% of Gross Profit
Operating Expenses	$30.06M	$26.86M	$15.60M
YoY Change	92.67%	145.77%	31.42%
Operating Profit		-$22.58M
YoY Change		81.33%
Interest Expense	$1.300M	$1.030M	$330.0K
YoY Change	293.94%	635.71%	-210.0%
% of Operating Profit
Other Income/Expense, Net		$1.034M
YoY Change		626.85%
Pretax Income	-$25.02M	-$21.54M	-$11.95M
YoY Change	109.37%	75.02%	-1.73%
Income Tax	$1.140M	-$6.000K	-$340.0K
% Of Pretax Income
Net Earnings	-$26.16M	-$21.54M	-$3.007M
YoY Change	770.0%	75.48%	-73.96%
Net Earnings / Revenue	-700.43%	-502.47%	-90.71%
Basic Earnings Per Share		-$0.87
Diluted Earnings Per Share	-$1.026M	-$0.87	-$158.3K
COMMON SHARES
Basic Shares Outstanding	25.46M shares	25.45M shares
Diluted Shares Outstanding		24.88M

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$218.1M	$233.9M	$119.9M
YoY Change	81.88%	252.79%	126.23%
Cash & Equivalents	$41.47M	$119.8M	$82.03M
Short-Term Investments	$176.6M	$114.2M	$37.90M
Other Short-Term Assets	$2.000M	$3.300M	$900.0K
YoY Change	122.22%	230.0%	50.0%
Inventory
Prepaid Expenses
Receivables	$2.400M	$2.590M	$2.274M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$222.5M	$239.9M	$123.1M
YoY Change	80.72%	249.16%	129.7%
LONG-TERM ASSETS
Property, Plant & Equipment	$557.0K	$515.8K	$860.0K
YoY Change	-35.23%	-14.03%	330.0%
Goodwill	$12.64M	$12.64M	$12.64M
YoY Change	0.0%
Intangibles		$29.00M	$29.00M
YoY Change
Long-Term Investments		$1.000M	$3.700M
YoY Change		-28.57%	37.04%
Other Assets	$3.348M		$340.0K
YoY Change	884.71%
Total Long-Term Assets	$45.54M	$43.10M	$46.19M
YoY Change	-1.39%	-1.28%	3.68%
TOTAL ASSETS
Total Short-Term Assets	$222.5M	$239.9M	$123.1M
Total Long-Term Assets	$45.54M	$43.10M	$46.19M
Total Assets	$268.0M	$283.0M	$169.3M
YoY Change	58.32%	151.98%	72.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.693M	$3.000M	$2.100M
YoY Change	75.86%	233.33%	-12.5%
Accrued Expenses	$9.679M	$6.517M	$6.139M
YoY Change	57.66%	1.83%	27.9%
Deferred Revenue	$5.100M		$45.79M
YoY Change	-88.86%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$18.47M	$14.61M	$13.49M
YoY Change	36.91%	19.75%	90.03%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$35.70M	$36.80M	$40.60M
YoY Change	-12.07%	-11.96%
Total Long-Term Liabilities	$38.92M	$38.93M	$42.69M
YoY Change	-8.84%	-26.49%	283.93%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.47M	$14.61M	$13.49M
Total Long-Term Liabilities	$38.92M	$38.93M	$42.69M
Total Liabilities	$57.39M	$53.54M	$56.18M
YoY Change	2.15%	-17.88%	208.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$341.8M	-$315.6M	-$251.0M
YoY Change	36.15%
Common Stock	$552.8M	$25.46K	$20.00K
YoY Change	2763835.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$210.7M	$229.4M	$113.1M
YoY Change
Total Liabilities & Shareholders Equity	$268.0M	$283.0M	$169.3M
YoY Change	58.32%	151.98%	72.58%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q4
OPERATING ACTIVITIES
Net Income	-$26.16M	-$21.54M	-$3.007M
YoY Change	770.0%	75.48%	-73.96%
Depreciation, Depletion And Amortization	$170.0K	$200.0K	$100.0K
YoY Change	70.0%	377.94%	400.0%
Cash From Operating Activities	-$16.73M	-$16.68M	-$9.770M
YoY Change	71.24%	52.19%	-11.5%
INVESTING ACTIVITIES
Capital Expenditures	-$210.0K	-$40.00K	-$360.0K
YoY Change	-41.67%	-92.0%	227.27%
Acquisitions
YoY Change
Other Investing Activities	-$61.95M	-$73.56M	-$1.310M
YoY Change	4629.01%	7183.17%	-108.3%
Cash From Investing Activities	-$62.16M	-$73.60M	-$1.670M
YoY Change	3622.16%	4774.17%	-110.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	600.0K	155.9M	66.23M
YoY Change	-99.09%	59842.31%	44053.33%
NET CHANGE
Cash From Operating Activities	-16.73M	-16.68M	-9.770M
Cash From Investing Activities	-62.16M	-73.60M	-1.670M
Cash From Financing Activities	600.0K	155.9M	66.23M
Net Change In Cash	-78.29M	65.57M	54.79M
YoY Change	-242.89%	-637.02%	1046.23%
FREE CASH FLOW
Cash From Operating Activities	-$16.73M	-$16.68M	-$9.770M
Capital Expenditures	-$210.0K	-$40.00K	-$360.0K
Free Cash Flow	-$16.52M	-$16.64M	-$9.410M
YoY Change	75.56%	59.08%	-13.91%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q4	us-gaap	Assets Current AssetsCurrent	123118512	USD
CY2018Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	0	USD
CY2017Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	3347213	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	515798	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	860026	USD
CY2018Q3	us-gaap	Security Deposit SecurityDeposit	950515	USD
CY2017Q4	us-gaap	Security Deposit SecurityDeposit	339558	USD
CY2018Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	29000000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	29000000	USD
CY2018Q3	us-gaap	Goodwill Goodwill	12638136	USD
CY2017Q4	us-gaap	Goodwill Goodwill	12638136	USD
CY2018Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	43104449	USD
CY2017Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	46184933	USD
CY2018Q3	us-gaap	Assets Assets	282977202	USD
CY2017Q4	us-gaap	Assets Assets	169303445	USD
CY2018Q3	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	2987565	USD
CY2017Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	2123939	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119752339	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	82033209	USD
CY2018Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	114187793	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	37914482	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2589862	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2273421	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3342759	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	897400	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	239872753	USD
CY2018Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5105104	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	5229227	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14609722	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13492166	USD
CY2018Q3	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	2107300	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Current DeferredTaxLiabilitiesCurrent	2135802	USD
CY2018Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	36819053	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	40555708	USD
CY2018Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	38934256	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	42691510	USD
CY2018Q3	us-gaap	Liabilities Liabilities	53543978	USD
CY2017Q4	us-gaap	Liabilities Liabilities	56183676	USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	25460	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	20138	USD
CY2018Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	545388704	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	364528037	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-354896	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-392391	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-315626044	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-251036015	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	229433224	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	282977202	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	169303445	USD
CY2017Q1	asmb	Development Milestone Payments DevelopmentMilestonePayments	630000000	USD
CY2017Q1	asmb	Commercial Milestone Payments CommercialMilestonePayments	2150000000	USD
	us-gaap	Revenues Revenues	11068773	USD
	us-gaap	Revenues Revenues	5703293	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19108918	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10929436	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51490220	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33628196	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7752493	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4180357	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	25992186	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12022357	USD
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	26861411	USD
CY2017Q3	us-gaap	Costs And Expenses CostsAndExpenses	15109793	USD
CY2018Q3	us-gaap	Revenues Revenues	4285848	USD
CY2017Q3	us-gaap	Revenues Revenues	2659613	USD
	us-gaap	Costs And Expenses CostsAndExpenses	77482406	USD
	us-gaap	Costs And Expenses CostsAndExpenses	45650553	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-22575563	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12450180	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-66413633	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-39947260	USD
CY2018Q3	us-gaap	Interest Income Other InterestIncomeOther	1116053	USD
CY2017Q3	us-gaap	Interest Income Other InterestIncomeOther	241326	USD
	us-gaap	Interest Income Other InterestIncomeOther	2015475	USD
	us-gaap	Interest Income Other InterestIncomeOther	617668	USD
CY2018Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-82070	USD
CY2017Q3	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-99068	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-232320	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-577300	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1033983	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	142258	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1783155	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	40368	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-21535038	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-12272019	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-8749	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-51203	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-138686	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax	-143562	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	25931	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	61081	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	176181	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	355942	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21517856	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12262141	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-64552534	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-39589096	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.87
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.71
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.95
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.30
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	24878413	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17367523	shares
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-6542	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-35903	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-40449	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-105416	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	113119769	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3762714	USD
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	21900943	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17326506	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4780955	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4876589	shares
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	41450363	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5635	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	194303	USD
CY2018Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	114187793	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	41261695	USD
CY2018Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	50178552	USD
CY2018Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	185687	USD
CY2018Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	51177942	USD
CY2018Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	192407	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1403051	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1273849	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	887253	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	413823	USD
CY2018Q3	us-gaap	Depreciation Depreciation	161484	USD
CY2017Q3	us-gaap	Depreciation Depreciation	41846	USD
	us-gaap	Depreciation Depreciation	473430	USD
	us-gaap	Depreciation Depreciation	124676	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4229895	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4518128	USD
CY2018Q3	asmb	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	1435902	USD
CY2017Q4	asmb	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	674686	USD
CY2018Q3	asmb	Accured General And Administrative Expenses Current AccuredGeneralAndAdministrativeExpensesCurrent	851256	USD
CY2017Q4	asmb	Accured General And Administrative Expenses Current AccuredGeneralAndAdministrativeExpensesCurrent	946186	USD
CY2018Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6517053	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6139000	USD
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	1900000	shares
CY2018Q3	asmb	Future Stock Based Compensation Expense Current FutureStockBasedCompensationExpenseCurrent	5058506	USD
CY2018Q3	asmb	Future Stock Based Compensation Expense Year Two FutureStockBasedCompensationExpenseYearTwo	10864062	USD
CY2018Q3	asmb	Future Stock Based Compensation Expense Year Three FutureStockBasedCompensationExpenseYearThree	3859597	USD
CY2018Q3	asmb	Future Stock Based Compensation Expense Year Four FutureStockBasedCompensationExpenseYearFour	973485	USD
CY2018Q3	asmb	Futurestockbasedcompensationexpenseyearfive Futurestockbasedcompensationexpenseyearfive	52638	USD
CY2018Q3	asmb	Future Stock Based Compensation Expense Total FutureStockBasedCompensationExpenseTotal	20808288	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M24D
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	120000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	231559	shares
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	343465	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	44.28
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	46.56
CY2018Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	45.70
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6005772	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2597101	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	21677510	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5833010	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-21541580	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12307922	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-64630478	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-39906892	USD
CY2018Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
	us-gaap	Trading Securities Unrealized Holding Gain Loss TradingSecuritiesUnrealizedHoldingGainLoss	37495	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	21677510	USD
CY2018Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	999390	USD
CY2018Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	6720	USD
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	7156	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	49.14
	asmb	Cost Of Reimbursable Expenses CostOfReimbursableExpenses	200000	USD
CY2017	asmb	Cost Of Reimbursable Expenses CostOfReimbursableExpenses	100000	USD
CY2018Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	500000	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	400000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1300000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1100000	USD
CY2018Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25460122	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20137974	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20137974	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25460122	shares
CY2018Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	50664	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	31844	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	44192	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Before Reclassification Adjustments Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesBeforeReclassificationAdjustmentsTax	89281	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	56139	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	37987	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	56139	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	221358	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	155425765	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax	11947	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13968933	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	155425765	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.43in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the condensed consolidated financial statements in conformity with the U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.4in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Significant estimates inherent in the preparation of the accompanying condensed consolidated financial statements include recoverability and useful lives (indefinite or finite) of intangible assets, assessment of impairment of goodwill, provisions for income taxes, amounts receivable under the collaboration agreement, and the fair value of stock options, restricted stock units (RSUs) granted to employees and directors.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.4in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates and assumptions.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-170423	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-48231171	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	11630144	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	129202	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	503115	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	115029814	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	40022384	USD
	us-gaap	Net Income Loss NetIncomeLoss	-39801476	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	41920838	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	26556566	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-73238178	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	21677510	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5833010	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-232320	USD
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-577300	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-40449	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-105416	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	316441	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1400374	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2445359	USD
CY2017Q1	us-gaap	Revenue Recognition Milestone Method Description RevenueRecognitionMilestoneMethodDescription	the Company is eligible to receive variable consideration in the form of cost-sharing reimbursements, up to approximately $630 million related to seven development milestones and up to approximately $2.15 billion related to 12 commercial development and sales milestones in connection with the successful development and commercialization of licensed compounds for up to six different indications.
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7903	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	938	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	49.14
	us-gaap	Net Income Loss NetIncomeLoss	-64590029	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	340158	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	863626	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1497524	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	378053	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1599689	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-3860778	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	46810840	USD
	asmb	Increase Decrease In Deferred Rent Noncurrent IncreaseDecreaseInDeferredRentNoncurrent	7903	USD
	asmb	Increase Decrease In Deferred Rent Noncurrent IncreaseDecreaseInDeferredRentNoncurrent	0	USD
	us-gaap	Increase Decrease In Security Deposits IncreaseDecreaseInSecurityDeposits	-610957	USD
	asmb	Accrued Offering Cost Related To Issuance Of Common Stock AccruedOfferingCostRelatedToIssuanceOfCommonStock	3762714	USD
	asmb	Accrued Offering Cost Related To Issuance Of Common Stock AccruedOfferingCostRelatedToIssuanceOfCommonStock	1010936	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	159188479	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1010936	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	37719130	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1327853	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28575085	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27247232	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued1 StockIssued1	8	USD
	asmb	Marketable Securities Available For Sale Change In Before Tax MarketableSecuritiesAvailableForSaleChangeInBeforeTax	49442	USD
	asmb	Marketable Securities Available For Sale Change In Before Tax MarketableSecuritiesAvailableForSaleChangeInBeforeTax	344457	USD
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	ASSEMBLY BIOSCIENCES, INC.
	dei	Entity Central Index Key EntityCentralIndexKey	0001426800
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	ASMB
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25463172	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30

Files In Submission

Name	View Source	Status
0001144204-18-058118-index-headers.html	Edgar Link	pending
0001144204-18-058118-index.html	Edgar Link	pending
0001144204-18-058118.txt	Edgar Link	pending
0001144204-18-058118-xbrl.zip	Edgar Link	pending
asmb-20180930.xml	Edgar Link	completed
asmb-20180930.xsd	Edgar Link	pending
asmb-20180930_cal.xml	Edgar Link	unprocessable
asmb-20180930_def.xml	Edgar Link	unprocessable
asmb-20180930_lab.xml	Edgar Link	unprocessable
asmb-20180930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv505055_10q.htm	Edgar Link	pending
tv505055_ex10-1.htm	Edgar Link	pending
tv505055_ex10-1img1.jpg	Edgar Link	pending
tv505055_ex10-1img10.jpg	Edgar Link	pending
tv505055_ex10-1img11.jpg	Edgar Link	pending
tv505055_ex10-1img12.jpg	Edgar Link	pending
tv505055_ex10-1img13.jpg	Edgar Link	pending
tv505055_ex10-1img14.jpg	Edgar Link	pending
tv505055_ex10-1img15.jpg	Edgar Link	pending
tv505055_ex10-1img16.jpg	Edgar Link	pending
tv505055_ex10-1img17.jpg	Edgar Link	pending
tv505055_ex10-1img18.jpg	Edgar Link	pending
tv505055_ex10-1img19.jpg	Edgar Link	pending
tv505055_ex10-1img2.jpg	Edgar Link	pending
tv505055_ex10-1img20.jpg	Edgar Link	pending
tv505055_ex10-1img3.jpg	Edgar Link	pending
tv505055_ex10-1img4.jpg	Edgar Link	pending
tv505055_ex10-1img5.jpg	Edgar Link	pending
tv505055_ex10-1img6.jpg	Edgar Link	pending
tv505055_ex10-1img7.jpg	Edgar Link	pending
tv505055_ex10-1img9.jpg	Edgar Link	pending
tv505055_ex31-1.htm	Edgar Link	pending
tv505055_ex31-2.htm	Edgar Link	pending
tv505055_ex32-1.htm	Edgar Link	pending
tv505055_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ASMB
Assembly Biosciences Inc Stock $asmb

2018 Q4 Form 10-Q Financial Statement

#000114420418058118 Filed on November 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASMB Assembly Biosciences Inc Stock $asmb

2018 Q4 Form 10-Q Financial Statement

#000114420418058118 Filed on November 08, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ASMB
Assembly Biosciences Inc Stock $asmb